J
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Jamjoom Pharmaceuticals Factory Company SJSC
SAU:4015
Price:
156
SAR
4.7%
Market Closed
Market Cap:
10.9B
SAR
Income Statement
Earnings Waterfall
Jamjoom Pharmaceuticals Factory Company SJSC
Jamjoom Pharmaceuticals Factory Company SJSC
|
Revenue
|
1.4B
SAR
|
|
Cost of Revenue
|
-526.6m
SAR
|
|
Gross Profit
|
863.9m
SAR
|
|
Operating Expenses
|
-452.5m
SAR
|
|
Operating Income
|
411.5m
SAR
|
|
Other Expenses
|
-873.5k
SAR
|
|
Net Income
|
410.6m
SAR
|
Income Statement
Jamjoom Pharmaceuticals Factory Company SJSC
Jamjoom Pharmaceuticals Factory Company SJSC
Currency: SAR
Millions
TTM
| Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
1 517
N/A
|
1 810
+19%
|
1 101
-39%
|
1 184
+8%
|
1 232
+4%
|
1 267
+3%
|
1 318
+4%
|
1 391
+5%
|
|
| Gross Profit | |||||||||
| Cost of Revenue |
(525)
|
(631)
|
(397)
|
(431)
|
(458)
|
(486)
|
(498)
|
(527)
|
|
| Gross Profit |
992
N/A
|
1 179
+19%
|
704
-40%
|
754
+7%
|
774
+3%
|
781
+1%
|
821
+5%
|
864
+5%
|
|
| Operating Income | |||||||||
| Operating Expenses |
(572)
|
(674)
|
(392)
|
(408)
|
(416)
|
(412)
|
(439)
|
(452)
|
|
| Selling, General & Administrative |
(522)
|
(616)
|
(353)
|
(376)
|
(384)
|
(380)
|
(402)
|
(418)
|
|
| Research & Development |
(50)
|
(59)
|
(24)
|
(32)
|
(32)
|
(32)
|
(25)
|
(35)
|
|
| Depreciation & Amortization |
0
|
0
|
(8)
|
0
|
0
|
0
|
(6)
|
0
|
|
| Other Operating Expenses |
0
|
0
|
(7)
|
0
|
0
|
0
|
(6)
|
0
|
|
| Operating Income |
420
N/A
|
504
+20%
|
312
-38%
|
346
+11%
|
358
+3%
|
369
+3%
|
381
+3%
|
411
+8%
|
|
| Pre-Tax Income | |||||||||
| Interest Income Expense |
(50)
|
(51)
|
3
|
(9)
|
(4)
|
3
|
2
|
22
|
|
| Non-Reccuring Items |
0
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
1
|
2
|
2
|
(0)
|
0
|
(1)
|
(1)
|
0
|
|
| Pre-Tax Income |
371
N/A
|
455
+23%
|
316
-31%
|
337
+7%
|
354
+5%
|
371
+5%
|
383
+3%
|
434
+13%
|
|
| Net Income | |||||||||
| Tax Provision |
(29)
|
(36)
|
(23)
|
(26)
|
(22)
|
(22)
|
(26)
|
(23)
|
|
| Income from Continuing Operations |
342
|
419
|
292
|
311
|
332
|
349
|
357
|
411
|
|
| Net Income (Common) |
342
N/A
|
419
+23%
|
292
-30%
|
311
+6%
|
332
+7%
|
349
+5%
|
357
+2%
|
411
+15%
|
|
| EPS (Diluted) |
4.89
N/A
|
5.99
+22%
|
4.18
-30%
|
4.44
+6%
|
4.74
+7%
|
4.99
+5%
|
5.09
+2%
|
5.87
+15%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
